These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36419585)

  • 1. [
    Pauwels E; Dekervel J; Verslype C; Clement PM; Dooms C; Baete K; Goffin K; Jentjens S; Van Laere K; Van Cutsem E; Deroose CM
    Am J Nucl Med Mol Imaging; 2022; 12(5):152-162. PubMed ID: 36419585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation-Based Index and
    Pauwels E; Van Binnebeek S; Vandecaveye V; Baete K; Vanbilloen H; Koole M; Mottaghy FM; Haustermans K; Clement PM; Nackaerts K; Van Cutsem E; Verslype C; Deroose CM
    J Nucl Med; 2020 Jul; 61(7):1014-1020. PubMed ID: 31806775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visual and whole-body quantitative analyses of
    Hotta M; Sonni I; Thin P; Nguyen K; Gardner L; Ciuca L; Hayrapetian A; Lewis M; Lubin D; Allen-Auerbach M
    Ann Nucl Med; 2024 Apr; 38(4):296-304. PubMed ID: 38252228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy.
    Boursier C; Zaragori T; Bros M; Bordonne M; Melki S; Taillandier L; Blonski M; Roch V; Marie PY; Karcher G; Imbert L; Verger A
    Eur Radiol; 2023 Oct; 33(10):7089-7098. PubMed ID: 37148355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of
    Lee H; Kipnis ST; Niman R; O'Brien SR; Eads JR; Katona BW; Pryma DA
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
    Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
    J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome of indigenous
    Sitani K; Parghane RV; Talole S; Basu S
    Br J Radiol; 2021 Jan; 94(1117):20201041. PubMed ID: 33095671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictive value of pretherapy [
    Akhavanallaf A; Peterson AB; Fitzpatrick K; Roseland M; Wong KK; El-Naqa I; Zaidi H; Dewaraja YK
    Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):2984-2996. PubMed ID: 37171633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of hitherto unknown brain meningioma detected on
    Parghane RV; Talole S; Basu S
    World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients receiving Concomitant
    Ballal S; Yadav MP; Tripathi M; Sahoo RK; Bal C
    J Nucl Med; 2022 Jul; ():. PubMed ID: 35863893
    [No Abstract]   [Full Text] [Related]  

  • 11. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of
    Adnan A; Basu S
    J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiomics-Based Texture Analysis of
    Atkinson C; Ganeshan B; Endozo R; Wan S; Aldridge MD; Groves AM; Bomanji JB; Gaze MN
    Front Oncol; 2021; 11():686235. PubMed ID: 34408979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial clinical evaluation of indigenous
    Parghane RV; Mitra A; Bannore TU; Rakshit S; Banerjee S; Basu S
    World J Nucl Med; 2021; 20(1):73-81. PubMed ID: 33850492
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE.
    Graf J; Pape UF; Jann H; Denecke T; Arsenic R; Brenner W; Pavel M; Prasad V
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):881-894. PubMed ID: 31414209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT.
    Zwirtz K; Hardt J; Acker G; Baur ADJ; Pavel M; Huang K; Brenner W; Prasad V
    Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745849
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes - [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18F]FDG PET/CT qualification in Polish multicentre experience - do we need [18F]FDG PET/CT for qualification to PRRT?
    Zemczak A; Kołodziej M; Gut P; Królicki L; Kos-Kudła B; Kamiński G; Ruchała M; Pawlak D; Kunikowska J
    Endokrynol Pol; 2020; 71(3):240-248. PubMed ID: 32293704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of
    Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S
    Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term prognostic factors for PRRT in neuroendocrine tumors.
    Trautwein NF; Schwenck J; Jacoby J; Reischl G; Fiz F; Zender L; Dittmann H; Hinterleitner M; la Fougère C
    Front Med (Lausanne); 2023; 10():1169970. PubMed ID: 37359009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relevance of Volumetric Parameters Applied to [
    Urso L; Castello A; Treglia G; Panareo S; Nieri A; Rambaldi I; Caracciolo M; Ortolan N; Uccelli L; Cittanti C; Castellani M; Bartolomei M
    Diagnostics (Basel); 2023 Feb; 13(4):. PubMed ID: 36832093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Safety and Efficacy of the Repeated PRRT with [
    Zemczak A; Gut P; Pawlak D; Kołodziej M; Królicki L; Kos-Kudła B; Ruchała M; Kamiński G; Kunikowska J
    Int J Endocrinol; 2021; 2021():6615511. PubMed ID: 33552155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.